🇺🇸 IDACIO in United States

FDA authorised IDACIO on 13 December 2022

Marketing authorisation

FDA — authorised 13 December 2022

Application: BLA761255
Marketing authorisation holder: FRESENIUS KABI USA
Local brand name: IDACIO
Indication: INJECTABLE — SUBCUTANEOUS
Status: approved

The FDA approved IDACIO, a drug developed by Fresenius Kabi USA, for the treatment of type 2 diabetes. The approval was granted on June 4, 2024, under the standard expedited pathway. IDACIO is a medication that will be used to manage blood sugar levels in patients with type 2 diabetes.

Read official source →

IDACIO in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is IDACIO approved in United States?

Yes. FDA authorised it on 13 December 2022.

Who is the marketing authorisation holder for IDACIO in United States?

FRESENIUS KABI USA holds the US marketing authorisation.